DIvO: Digital Imaging Versus Ophthalmoscopy

Sponsor
Cambridge University Hospitals NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05282147
Collaborator
(none)
140,000
1
42

Study Details

Study Description

Brief Summary

Cataract (cloudiness of the lens) is the major cause of avoidable child blindness in the world and affects 1 in 3000 UK infants. Screening may fail to detect a cataract in an affected child (false-negative) or mistakenly suggest there is a cataract (false positive) triggering urgent unnecessary referral.

Screening is currently undertaken using an ophthalmoscope into the eye to assess the reddish reflected light (red-reflex). This study aims to test if screening using a new hand-held digital imaging device (Neocam) is more accurate than the ophthalmoscope for newborn eye screening.

Condition or Disease Intervention/Treatment Phase
  • Device: Neocam
N/A

Detailed Description

Cataract (cloudiness of the lens) is the major cause of avoidable child blindness in the world and affects 1 in 3000 UK infants. Cataracts are present in both eyes in more than half of the babies affected. Surgery is required by 8 weeks of age to prevent permanent visual impairment at this critical time of vision and brain development. All UK babies are examined (screened) for cataract twice within the first 8 weeks of life but late diagnosis continues to be a problem, causing avoidable visual impairment in some affected children.

Screening may fail to detect a cataract in an affected child (false-negative) or mistakenly suggest there is a cataract (false positive) triggering urgent unnecessary referral, parental anxiety and wasted NHS resources. Screening is currently performed by midwives and doctors shining a bright white light torch (an ophthalmoscope) into the eye to assess the reddish reflected light (red-reflex), similar to "red eye" seen in flash photos. Cataract causes a dark shadow on the red-reflex but the test can be difficult because bright light causes the pupils to constrict and the babies to forcefully shut their eyes. Assessment is particularly difficult in ethnic minority infants since eye pigmentation affects the hue and brightness of the red-reflex.

This study aims to test if screening using a new hand-held digital imaging device (Neocam) is more accurate than the ophthalmoscope for newborn eye screening. Neocam painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash. Its infrared light causes no pupil constriction or avoidance response and the reflection is bright and consistent regardless of the baby's ethnicity. Its brief green flash and immediate imaging allows a photo of the red-reflex to be captured before the pupil has time to constrict.

To compare the accuracy of both tests, the investigators seek to enrol 140,000 newborn babies in a two year study period. All babies will have both the current ophthalmoscope screening test and additional Neocam imaging. If either test is potentially abnormal, the baby will be referred for specialist examination.

A more accurate screening test could prevent life-long disability and reduce costs to the NHS and society. This study will allow a future estimation of what these savings might be and whether changing to a digital imaging screening service might be justified. The result may have an impact on eye screening world-wide to prevent childhood blindness from cataract.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140000 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Can the Diagnostic Accuracy of Newborn Eye Screening for Congenital Cataract be Improved With Digital Dual Light Source Imaging? The Digital Imaging vs Ophthalmoscopy (DIvO)Study.
Anticipated Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Other: Babies undergoing newborn eye screening

Babies having newborn eye screening with the intervention (Digital Imaging) technique in addition to the standard ophthalmoscopic technique.

Device: Neocam
Screening within 72 hours of birth will be completed using the digital imaging device Neocam which painlessly images the eye's reflection firstly to infrared light and then to a brief green light flash.

Outcome Measures

Primary Outcome Measures

  1. Sensitivity of the screening evaluation of the Neocam (intervention) test [2 years]

    The proportion of patients correctly identified as having cataract by a positive Neocam screening test result. Where a higher value indicates better sensitivity of the screening test for presence of cataract.

  2. Specificity of the screening evaluation of the Neocam (intervention) test [2 years]

    The proportion of patients correctly identified as not having cataract by a negative Neocam screening test result. Where a higher value indicates better specificity of the screening test for absence of cataract.

  3. Sensitivity of the screening evaluation of the standard test [2 years]

    The proportion of patients correctly identified as having cataract by a positive standard screening test result. Where a higher value indicates better sensitivity of the screening test for presence of cataract.

  4. Specificity of the screening evaluation of the standard test [2 years]

    The proportion of patients correctly identified as not having a cataract by a negative standard screening result. Where a higher value indicates better specificity of the screening test for absence of cataract.

Secondary Outcome Measures

  1. Usability feedback [2 years]

    Qualitative usability feedback and test preference using screener questionnaire.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 72 Hours
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

All newborn babies having the newborn physical examination

Exclusion Criteria:

None

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

Investigators

  • Principal Investigator: Louise Allen, Cambridge University Hospitals NHS Foundation Trust

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Louise Allen, Chief Investigator, Cambridge University Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT05282147
Other Study ID Numbers:
  • CCTU0276
First Posted:
Mar 16, 2022
Last Update Posted:
Apr 7, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2022